Citations

Clear

815 citation(s) found for "Tang, AH".

Abstract We003: Identification of CircRNA-miRNA-mRNA Regulatory Network and Crucial Signaling Pathways Related to Cardiomyocyte Proliferation in Neonatal Mice
Tang, Ling , Nyarige, Verah , Li, Pengsheng , Zhu, Wuqiang, Zhu, Wuqiang

Mayo Clinic

Circulation Research | October 9, 2024 | Volume: 135 | Issue: Suppl_1 | Pages: AWe003-AWe003

10.1161/res.135.suppl_1.we003 Get It

Introduction: Neonatal pig hearts exhibit remarkable regenerative capacity within two days post-birth. In this study, we propose that a comprehensive multiomics analysis encompassing circRNA, miRNA, and mRNA data from neonatal mouse hearts can unveil intricate circRNA-miRNA-mRNA relationships associated with cardiac regeneration. Our aim is to identify new novel circRNAs and miRNAs implicated in cardiomyocyte proliferation through leveraging multiomics analysis. Methods: Utilizing neonatal mouse hearts, we conducted circRNA, miRNA, and mRNA sequencing across four different postnatal days (P1, P3, P7, and P28; n=6, encompassing both males and females). We employed integrative bioinformatics analyses across distinct experimental designs (P1 vs P3, P1 vs P7, and P1 vs P28). Back splice junctions generated by CIRCexplorer2’s parse command was utilized to annotate sequenced circRNAs as known or novel. Validation of circRNA, miRNA, and mRNA expression levels was achieved through qRT-PCR, while protein expression levels were assessed via western blotting. Fluorescence in situ hybridization (FISH) technology was employed to determine circRNA localization. The functional significance of key genes involved in cardiomyocyte proliferation was assessed via siRNA-mediated knockdown of circRNAs and miRNAs, accompanied by cell cycle assessment using bioluminescence assay and immunostaining. Results: Intersection of differentially expressed target genes from circRNA, miRNA, and mRNA analyses at each experimental design facilitated the construction of circRNA-miRNA-mRNA regulatory networks, aiding in the development of cardiac regeneration-related regulatory networks and inference of novel relationships between circRNA, miRNA, and mRNA. Integrative bioinformatics analysis revealed significant alterations in circRNA-miRNA-mRNA expression profiles during postnatal cardiomyocyte maturation in mice. Pathway enrichment analysis identified several differentially expressed circRNAs enriched in cell division and proliferation-related pathways. qPCR and cell cycle studies identified 17 potential circRNAs associated with cardiomyocyte proliferation in mice, with knockdown of these circRNAs significantly impacting cardiomyocyte cell cycle. Conclusion: Our findings suggest a crucial role for circRNAs in the regulation of neonatal myocardial regeneration.
Defining standards for fluoroscopy in gastrointestinal endoscopy using Delphi methodology
Khalaf, Kareem , Pawlak, Katarzyna M. , Alkandari, Asma , Baron, Todd H. , Bechara, Robert , Binda, Cecilia , Chen, Yen‐I , Moura, Eduardo Guimarães Hourneaux de , Forbes, Nauzer , James, Paul, Martin, Harry , May, Gary R. , Mosko, Jeffrey D. , Oyeleke, Ganiyat K. , Petersen, Bret T. , Saxena, Payal , Sethi, Amrita , Sharaiha, Reem Z. , Tang, Raymond S. , Villarroel, Mariano , Hooft, Jeanin E. van , Renteln, Daniel von , Walsh, Catharine M. , Aberin, Tricia, Banavage, Dawn, Chen, Jowell Akina, Clancy, James, Drake, Heather, Im, Melanie, Low, Chooi Peng, Myszko, Alexandra, Navarro, Krista, Redman, Jessica, Reyes, Wayne, Weinstein, Faina, Na, Caleb, Tham, Daniel , He, Tony , Malipatil, Sharan B., Gimpaya, Nikko , Kundra, Arjun , Grover, Samir C. , Barkun, Alan N , Bechara, Robert , Binda, Cecilia , de Moura, Eduardo , Hassan, Cesare , Kahaleh, Michel , Sharaiha, Reem Z , Villarroel, Mariano , van Hooft, Jeanin E , Voermans, Rogier P , von Renteln, Daniel , Walsh, Catharine M , Gupta, Sunil , Fujiyoshi, Yusuke , Grover, Samir C , Causada Calo, Natalia S , Pawlak, Katarzyna M , Adler, Douglas G. , Barkun, Alan , Berzin, Tyler M. , Cai, Ming‐Yan , Carrara, Silvia , Fugazza, Alessandro , Hassan, Cesare , James, Paul D., Kahaleh, Michel , Maselli, Roberta , Repici, Alessandro , Spadaccini, Marco , Teshima, Christopher , Voermans, Rogier P. , Clancy, James, Reyes, Wayne, Gupta, Sunil , Mokhtar, Ahmed H., Gholami, Reza

Mayo Clinic

Endoscopy International Open | October 7, 2024 | Volume: 12 | Issue: 11 | Pages: E1315-E1325

10.1055/a-2427-3893 | PMID 39559412 Get It

Abstract Background and study aims Use of fluoroscopy in gastrointestinal endoscopy is an essential aid in advanced endoscopic interventions. However, it also raises concerns about radiation exposure. This study aimed to develop consensus-based statements for safe and effective use of fluoroscopy in gastrointestinal endoscopy, prioritizing the safety and well-being of healthcare workers and patients. Methods A modified Delphi approach was employed to achieve consensus over three rounds of surveys. Proposed statements were generated in Round 1. In the second round, panelists rated potential statements on a 5-point scale, with consensus defined as ≥80% agreement. Statements were subsequently prioritized in Round 3, using a 1 (lowest priority) to 10 (highest priority) scale. Results Forty-six experts participated, consisting of 34 therapeutic endoscopists and 12 endoscopy nurses from six continents, with an overall 45.6% female representation (n = 21). Forty-three item statements were generated in the first round. Of these, 31 statements achieved consensus after the second round. These statements were categorized into General Considerations (n = 6), Education (n = 10), Pregnancy (n = 4), Family Planning (n = 2), Patient Safety (n = 4), and Staff Safety (n = 5). In the third round, accepted statements received mean priority scores ranging from 7.28 to 9.36, with 87.2% of statements rated as very high priority (mean score ≥ 9). Conclusions This study presents consensus-based statements for safe and effective use of fluoroscopy in gastrointestinal endoscopy, addressing the well-being of healthcare workers and patients. These consensus-based statements aim to mitigate risks associated with radiation exposure while maintaining benefits of fluoroscopy, ultimately promoting a culture of safety in healthcare settings.
OmicsFootPrint: a framework to integrate and interpret multi-omics data using circular images and deep neural networks
Prodduturi, Naresh, Thompson, Kevin J. , Weinshilboum, Richard M. , O’Sullivan, Ciara C. , Tizhoosh, Hamid R. , Klee, Eric W. , Wang, Liewei , Goetz, Matthew P. , Tang, Xiaojia , Thompson, Kevin J , Weinshilboum, Richard, O'Sullivan, Ciara C, Suman, Vera, Kalari, Krishna R , Goetz, Matthew P , Klee, Eric W , Tizhoosh, Hamid R , Tang, Xiaojia , Weinshilboum, Richard M. , Boughey, Judy C. , Suman, Vera J. , Kalari, Krishna R.

Mayo Clinic

Nucleic Acids Research | October 6, 2024 | Volume: 52 | Issue: 21 | Pages: e99-e99

10.1093/nar/gkae915 | PMID 39445795 Get It

Abstract The OmicsFootPrint framework addresses the need for advanced multi-omics data analysis methodologies by transforming data into intuitive two-dimensional circular images and facilitating the interpretation of complex diseases. Utilizing deep neural networks and incorporating the SHapley Additive exPlanations algorithm, the framework enhances model interpretability. Tested with The Cancer Genome Atlas data, OmicsFootPrint effectively classified lung and breast cancer subtypes, achieving high area under the curve (AUC) scores—0.98 ± 0.02 for lung cancer subtype differentiation and 0.83 ± 0.07 for breast cancer PAM50 subtypes, and successfully distinguished between invasive lobular and ductal carcinomas in breast cancer, showcasing its robustness. It also demonstrated notable performance in predicting drug responses in cancer cell lines, with a median AUC of 0.74, surpassing nine existing methods. Furthermore, its effectiveness persists even with reduced training sample sizes. OmicsFootPrint marks an enhancement in multi-omics research, offering a novel, efficient and interpretable approach that contributes to a deeper understanding of disease mechanisms.
Ibrutinib Promotes Atrial Fibrillation by Disrupting A-Kinase Anchoring Protein 1-Mediated Mitochondrial Quality Surveillance in Cardiomyocytes
Li, Yukun , Liu, Xinmeng , Lin, Rong, Peng, Xiaodong , Wang, Xuesi , Meng, Fanchao , Jin, Shuqi , Lv, Wenhe , Liu, Xiaoying, Du, Zhuohang, Wen, Songnan, Bai, Rong , Ruan, Yanfei , Tang, Ribo , Li, Yukun , Zhou, Hao , Zou, Rongjun , Liu, Nian Bao

Mayo Clinic

Research | October 2, 2024 | Volume: 7 | Issue: No issue available | Pages: No page available

10.34133/research.0509 | PMID 39469220 Get It

Background: Ibrutinib, a potent Bruton’s tyrosine kinase inhibitor with marked efficacy against hematological malignancies, is associated with the heightened risk of atrial fibrillation (AF). Although ibrutinib-induced AF is linked to enhanced oxidative stress, the underlying mechanisms remain unclear. Objective: This research aimed to explore the molecular mechanism and regulatory target in ibrutinib-induced AF. Methods: We performed in vivo electrophysiology studies using ibrutinib-treated mice, and then employed proteomic and single-cell transcriptomic analyses to identify the underlying targets and mechanisms. The effects of A-kinase anchoring protein 1 (AKAP1) depletion on mitochondrial quality surveillance (MQS) were evaluated using both in vivo and ex vivo AKAP1 overexpression models. Results: Atrial AKAP1 expression was significantly reduced in ibrutinib-treated mice, leading to inducible AF, atrial fibrosis, and mitochondrial fragmentation. These pathological changes were effectively mitigated in an overexpression model of ibrutinib-treated mice injected with an adeno-associated virus carrying Akap1. In ibrutinib-treated atrial myocytes, AKAP1 down-regulation promoted dynamin-related protein 1 (DRP1) translocation into mitochondria by facilitating DRP1 dephosphorylation at Ser637, thereby mediating excessive mitochondrial fission. Impaired MQS was also suggested by defective mitochondrial respiration, mitochondrial metabolic reprogramming, and suppressed mitochondrial biogenesis, accompanied by excessive oxidative stress and inflammatory activation. The ibrutinib-mediated MQS disturbance can be markedly improved with the inducible expression of the AKAP1 lentiviral system. Conclusions: Our findings emphasize the key role of AKAP1-mediated MQS disruption in ibrutinib-induced AF, which explains the previously observed reactive oxygen species overproduction. Hence, AKAP1 activation can be employed to prevent and treat ibrutinib-induced AF.
Prostate Cancer Progression Modeling Provides Insight into Dynamic Molecular Changes Associated with Progressive Disease States
Chen, Runpu , Tang, Li , Melendy, Thomas , Yang, Le , Goodison, Steve , Sun, Yijun

Mayo Clinic

Cancer Research Communications | September 30, 2024 | Volume: 4 | Issue: 10 | Pages: 2783-2798

10.1158/2767-9764.crc-24-0210 | PMID 39347576 Get It

Abstract Prostate cancer is a significant health concern and the most commonly diagnosed cancer in men worldwide. Understanding the complex process of prostate tumor evolution and progression is crucial for improved diagnosis, treatments, and patient outcomes. Previous studies have focused on unraveling the dynamics of prostate cancer evolution using phylogenetic or lineage analysis approaches. However, those approaches have limitations in capturing the complete disease process or incorporating genomic and transcriptomic variations comprehensively. In this study, we applied a novel computational approach to derive a prostate cancer progression model using multidimensional data from 497 prostate tumor samples and 52 tumor-adjacent normal samples obtained from The Cancer Genome Atlas study. The model was validated using data from an independent cohort of 545 primary tumor samples. By integrating transcriptomic and genomic data, our model provides a comprehensive view of prostate tumor progression, identifies crucial signaling pathways and genetic events, and uncovers distinct transcription signatures associated with disease progression. Our findings have significant implications for cancer research and hold promise for guiding personalized treatment strategies in prostate cancer. Significance: We developed and validated a progression model of prostate cancer using >1,000 tumor and normal tissue samples. The model provided a comprehensive view of prostate tumor evolution and progression.
Novel Quantitative Liver Steatosis Assessment Method With Ultrasound Harmonic Imaging
Zhang, Jingke , Huang, Chengwu , Tang, Shanshan , Liu, Hui , DeRuiter, Ryan M. , Petersen, Kendra E , Knoll, Kate M , Robinson, Kathryn, Watt, Kymberly D., Callstrom, Matthew R. , Chen, Shigao , Petersen, Kendra E. , Zhang, Jingke , Lok, U-Wai , Liu, Hui , DeRuiter, Ryan , Petersen, Kendra, Knoll, Kate, Watt, Kymberly, Callstrom, Matthew, Huang, Chengwu , Gong, Ping , Lok, U‐Wai , Robinson, Kathryn

Mayo Clinic

Journal of Ultrasound in Medicine | September 24, 2024 | Volume: 44 | Issue: 1 | Pages: 77-85

10.1002/jum.16582 | PMID 39315751 Get It

ObjectivesMetabolic dysfunction‐associated steatotic liver disease (MASLD) is the most prevalent liver disorder in Western countries, with approximately 20%–30% of the MASLD patients progressing to severe stages. There is an urgent need for noninvasive, cost‐effective, widely accessible, and precise biomarkers to evaluate liver steatosis. This study aims to assess and compare the diagnostic performance of a novel reference frequency method‐based ultrasound attenuation coefficient estimation (ACE) in both fundamental (RFM‐ACE‐FI) and harmonic (RFM‐ACE‐HI) imaging for detecting and grading liver steatosis.MethodsAn Institutional Review Board‐approved prospective study was carried out between December 2018 and October 2022. A total number of 130 subjects were enrolled in the study. The correlation between RFM‐ACE‐HI values and magnetic resonance imaging proton density fat fraction (MRI‐PDFF), as well as between RFM‐ACE‐FI values and MRI‐PDFF were calculated. The diagnostic performance of RFM‐ACE‐FI and RFM‐ACE‐HI was evaluated using receiver operating characteristic (ROC) curve analysis, as compared to MRI‐PDFF. The reproducibility of RFM‐ACE‐HI was assessed by interobserver agreement between two sonographers.ResultsA strong correlation was observed between RFM‐ACE‐HI and MRI‐PDFF, with R = 0.88 (95% confidence interval [CI]: 0.83–0.92; P < .001), while the correlation between RFM‐ACE‐FI and MRI‐PDFF was R = 0.65 (95% CI: 0.50–0.76; P < .001). The area under the ROC (AUROC) curve for RFM‐ACE‐HI in staging liver steatosis grades of S ≥ 1 and S ≥ 2 was 0.97 (95% CI: 0.91–0.99; P < .001) and 0.98 (95% CI: 0.93–1.00; P < .001), respectively, and 0.76 (95% CI: 0.65–0.85) and 0.80 (95% CI: 0.70–0.88) for RFM‐ACE‐FI, respectively. Great reproducibility was achieved for RFM‐ACE‐HI, with an interobserver agreement of R = 0.97 (95% CI: 0.94–0.99; P < .001).ConclusionsThe novel RFM‐ACE‐HI method offered high liver steatosis diagnostic accuracy and reproducibility, which has important clinical implications for early disease intervention and treatment evaluation.
Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension
Tang, Wenze , Tsang, Yuen, Panjabi, Sumeet , Burger, Charles D.

Mayo Clinic

JAMA Network Open | September 23, 2024 | Volume: 7 | Issue: 9 | Pages: e2434691

10.1001/jamanetworkopen.2024.34691 | PMID 39312239 Get It

ImportanceA subgroup analysis of a randomized clinical trial established the efficacy of selexipag plus background therapy (monotherapy or double oral therapy [DOT]) vs placebo plus background therapy and found that the addition of selexipag within 6 months had an added benefit. However, the timing of selexipag addition to DOT and the incremental benefit in clinical practice is not well studied.ObjectiveTo compare triple oral therapy (TOT) consisting of selexipag, endothelin receptor antagonist (ERA), and phosphodiesterase type 5 inhibitor (PDE5i) vs DOT consisting of ERA and PDE5i.Design, Setting, and ParticipantsThis comparative effectiveness study was conducted using data from the US Komodo claims database to emulate a randomized trial. Patients aged 18 years or older with pulmonary arterial hypertension (PAH) treated with ERA plus PDE5i with records from July 2015 through June 2022 were duplicated to TOT and DOT and artificially censored when observed treatment deviated from assigned treatment. Hypothetical randomization was emulated using inverse probability of treatment weighting, and the study accounted for censoring-induced selection bias using inverse probability of censoring weighting. A pooled logistic model estimated the per-protocol difference between treatment groups. Data were analyzed from November 2022 through July 2023.InterventionsTOT (addition of selexipag within 3, 6, and 12 months of initiating DOT) vs DOT.Main Outcomes and MeasuresAdjusted risk of all-cause hospitalization, PAH-related hospitalization, and PAH-related disease progression over a 2-year follow-up.ResultsA total of 2966 patients with PAH (mean [SD] age, 54.3 [14.0] years; 2125 female [71.6%]) met eligibility criteria. Adding selexipag within 6 months of ongoing DOT was associated with a reduction in risk for all-cause hospitalization (adjusted hazard ratio [aHR], 0.82; 95% CI, 0.72-0.94), PAH-related hospitalization (aHR, 0.81; 95% CI, 0.70-0.95), and PAH-related progression (aHR, 0.82; 95% CI, 0.70-0.95) vs DOT alone. There were no associations if selexipag was initiated within 12 months for all-cause hospitalization, PAH-related hospitalization, or PAH-related disease progression. The association remained with a greater decrease in risk for disease progression vs DOT for selexipag initiation within 3 months (aHR, 0.74; 95% CI, 0.61-0.90).Conclusions and RelevanceThis study found that early selexipag addition to ERA plus PDE5i was associated with a reduction in risk of hospitalization and disease progression. These findings suggest that delays in selexipag initiation likely contribute to suboptimal patient and health system outcomes.
VaxBot-HPV: A GPT-based Chatbot for Answering HPV Vaccine-related Questions
Li, Yiming , Li, Jianfu , Li, Manqi , Yu, Evan , Tao, Cui , Li, Yiming , Amith, Muhammad , Tang, Lu , Savas, Lara S. , Cui, Licong

Mayo Clinic

No container title available | September 11, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4876692/v1 | PMID 39315262 Get It

Abstract Background: HPV vaccine is an effective measure to prevent and control the diseases caused by Human Papillomavirus (HPV). This study addresses the development of VaxBot-HPV, a chatbot aimed at improving health literacy and promoting vaccination uptake by providing information and answering questions about the HPV vaccine; Methods: We constructed the knowledge base (KB) for VaxBot-HPV, which consists of 451 documents from biomedical literature and web sources on the HPV vaccine. We extracted 202 question-answer pairs from the KB and 39 questions generated by GPT-4 for training and testing purposes. To comprehensively understand the capabilities and potential of GPT-based chatbots, three models were involved in this study : GPT-3.5, VaxBot-HPV, and GPT-4. The evaluation criteria included answer relevancy and faithfulness; Results: VaxBot-HPV demonstrated superior performance in answer relevancy and faithfulness compared to baselines (Answer relevancy: 0.85; Faithfulness: 0.97) for the test questions in KB, (Answer relevancy: 0.85; Faithfulness: 0.96) for GPT generated questions; Conclusions: This study underscores the importance of leveraging advanced language models and fine-tuning techniques in the development of chatbots for healthcare applications, with implications for improving medical education and public health communication.
Lymph node staging and treatment in pediatric patients with soft tissue sarcomas: A consensus opinion from the Children’s Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe
Scheltinga, Scheila E. J. Terwisscha van, Keizer, Bart de , McCarville, M. Beth , Casey, Dana L. , Walterhouse, David , Hiemcke‐Jiwa, Laura S. , Franzius, Christiane, Vokuhl, Christian , Birz, Suzi , Rodeberg, David A. , Casey, Dana L , de Keizer, Bart , Schoot, Reineke A , Routh, Jonathan C. , Seitz, Guido , Kao, Simon C. , Shulkin, Barry L. , Ewijk, Roelof van , Allen‐Rhoades, Wendy , Mercolini, Federico , Merks, Johannes H M , Orbach, Daniel , Kapadia, Tejas , Fajardo, Raquel Dávila , Corti, Federica De , Tang, Vivian , Metts, Jonathan L. , Oberoi, Saphna , Dasgupta, Roshni

Mayo Clinic

No container title available | August 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.172445880.02878798/v1 Get It

Accurate staging of nodal involvement in pediatric sarcoma patients is important to determine correct systemic and local therapy, with the goal to reduce subsequent recurrences. However, differences in lymph node staging strategies, definitions, and treatment protocols between the Children’s Oncology Group (COG), European Pediatric Soft Tissue Sarcoma Study Group (EpSSG), and the Cooperative Weichteil Sarkom Studiengruppe (CWS), complicate comparisons. In this article we try to establish internationally recognized recommendations for lymph node assessment and treatment of children and adolescents diagnosed with RMS and NRSTS according to the Consensus Conference Standard Operating Procedure methodology.